Project Grant R44CA302180
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11790, USA
Similar Awards
- This $1,313,567 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Cytoagents Inc., a Pittsburgh-based pharmaceutical company, in developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. CRS is a severe and potentially life-threatening immune-mediated toxicity that can occur with CAR T-cell treatments for hematologic malignancies. The...
- This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapy for acute myeloid leukemia (AML) with the chromosome inversion inv(16). The $545,170 award to Versiti Wisconsin, Inc. aims to characterize the mechanisms by which the oncogenic fusion protein CBFB-SMMHC activates the translation initiation factor EIF4G1, leading to AML transformation. The research will test whether inhibiting EIF4G1 can overcome...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This $738,698 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope supports research on a novel anti-CD38 targeted alpha therapy (TAT) combined with total marrow irradiation (TMLI) for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years old. The goal is to develop an innovative, organ-sparing radiotherapy approach that can safely escalate the radiation...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,625.00 to Cellchorus Inc., a Houston-based company specializing in advanced cell analysis technologies, to develop a high-throughput platform for profiling the functional signatures of CAR T cells from patients with relapsed/refractory large B cell lymphoma (r/r LBCL). The goal is to create a scalable, AI-powered imaging technology called Time-lapse Imaging Microscopy in...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...